Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACT: Allogeneic Cell Therapy in Refractory T-Cell Lymphoma
NCT07920393Phase 2Not yet recruiting
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Nov 2026
- Primary completion
- May 2031
01
Overview
Phase 2, open-label, single-arm trial in peripheral T-cell lymphoma (PTCL), sponsored by Universitätsmedizin Göttingen. Primary endpoint: Progression-Free Survival at 24 months. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07920393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07920393.